Randomized trial of 3-dose regimens of tafenoquine (WR238605) versus low-dose primaquine for preventing Plasmodium vivax malaria relapse. - Test2 - elhamkhani - TriplyDB

Randomized trial of 3-dose regimens of tafenoquine (WR238605) versus low-dose primaquine for preventing Plasmodium vivax malaria relapse.

Randomized trial of 3-dose regimens of tafenoquine (WR238605) versus low-dose primaquine for preventing Plasmodium vivax malaria relapse.

http://www.wikidata.org/entity/Q41913336

about

Tafenoquine for preventing relapse in people with Plasmodium vivax malaria Tafenoquine for Plasmodium vivax malaria infection Primaquine for preventing relapse in people with Plasmodium vivax malaria treated with chloroquine Primaquine for preventing relapses in people with Plasmodium vivax malaria Tafenoquine and its potential in the treatment and relapse prevention of Plasmodium vivax malaria: the evidence to date Primaquine in vivax malaria: an update and review on management issues A plant-derived morphinan as a novel lead compound active against malaria liver stages Understanding the clinical spectrum of complicated Plasmodium vivax malaria: a systematic review on the contributions of the Brazilian literature Resistance to therapies for infection by Plasmodium vivax Increased bioavailability of primaquine using poly(ethylene oxide) matrix extended-release tablets administered to beagle dogs.Lipophilic bisphosphonates are potent inhibitors of Plasmodium liver-stage growth.Antimalarial activities of new pyrrolo[3,2-f]quinazoline-1,3-diamine derivatives.Antimalarial compounds in Phase II clinical development.Tafenoquine at therapeutic concentrations does not prolong Fridericia-corrected QT interval in healthy subjects.Radical curative efficacy of tafenoquine combination regimens in Plasmodium cynomolgi-infected Rhesus monkeys (Macaca mulatta)Primaquine and relapses of Plasmodium vivax. Meta analysis of controlled clinical trials.Exposure-Response Analyses for Tafenoquine after Administration to Patients with Plasmodium vivax Malaria Single-dose radical cure of Plasmodium vivax: a step closer.Atovaquone/proguanil for the prophylaxis and treatment of malaria.Antimalarial drug therapy: the role of parasite biology and drug resistance.Antiparasitic activities and toxicities of individual enantiomers of the 8-aminoquinoline 8-[(4-amino-1-methylbutyl)amino]-6-methoxy-4-methyl-5-[3,4-dichlorophenoxy]quinoline succinate Tafenoquine: a promising new antimalarial agent.Clinical development of new prophylactic antimalarial drugs after the 5th Amendment to the Declaration of Helsinki.Management of relapsing Plasmodium vivax malaria Pharmacokinetic interactions and safety evaluations of coadministered tafenoquine and chloroquine in healthy subjects.Pharmacokinetic Interactions between Tafenoquine and Dihydroartemisinin-Piperaquine or Artemether-Lumefantrine in Healthy Adult Subjects Tafenoquine and NPC-1161B require CYP 2D metabolism for anti-malarial activity: implications for the 8-aminoquinoline class of anti-malarial compounds.Assessment of the prophylactic activity and pharmacokinetic profile of oral tafenoquine compared to primaquine for inhibition of liver stage malaria infections Therapy of vector-borne protozoan infections in nonendemic settings.Emerging drugs for malaria.Evolution from double to triple-antimalarial drug combinations.Hemolytic Potential of Tafenoquine in Female Volunteers Heterozygous for Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency (G6PD Mahidol Variant) versus G6PD-Normal Volunteers.Increased glycolytic ATP synthesis is associated with tafenoquine resistance in Leishmania major Antifungal drugs: predicting clinical efficacy with pharmacodynamics.Synthesis of [13C6]primaquine.Effects of supportive-expressive group therapy in breast cancer patients with affective disorders: a pilot study.A randomized, double-blind, active-control trial to evaluate the efficacy and safety of a three day course of tafenoquine monotherapy for the treatment of Plasmodium vivax malaria.Chloroquine-Primaquine versus Chloroquine Alone to Treat Vivax Malaria in Afghanistan: An Open Randomized Superiority Trial.Occupational asthma from tafenoquine in the pharmaceutical industry: implications for QSAR.Recent updates in the discovery and development of novel antimalarial drug candidates

P2860

Q24186356-86FCF746-0D33-4958-A282-DD7783F9F25A Q24200381-63D26A1D-372D-468E-B6BD-3335536E0F7B Q24202900-F7C27812-A248-48A7-95B2-21FE1BEB457A Q24246197-9631565B-B737-4923-A8CF-EFA592AFFF88 Q26741307-C8346279-3B1B-400E-994E-44C3B944FDA8 Q27003856-F53C3AA2-5D66-414A-932F-F84D352D500A Q28469086-B042425E-D895-4CD7-B42A-C1D5F498DBA5 Q33399080-4F534A20-989F-4121-89BD-64EC7AF1D761 Q33481576-81D88319-79C5-477E-A760-2CBE6D3142EC Q33908425-EF30AF82-C919-41D9-B8D2-33206D804E64 Q33962882-9345E782-DC24-4411-B36E-304017CF7BB5 Q34228300-8C0DA0EE-9841-4EC6-96AB-8B190EBE017D Q34456807-469C0CBF-13BB-4766-8419-ABB088A4F11C Q34811224-A1265844-8BAA-4EFE-9001-795A6CACB6DC Q35181605-84CA5C47-81D8-4FB2-879F-2341E97170AB Q35555054-51DF9BDB-A9E9-40AB-97D7-BAE36B34FE3D Q36075824-6CEF4213-3769-4FC9-AD80-5CE8DB20B056 Q36232674-A6FFBA5C-F31D-455B-8798-9CFDD7C5D256 Q36322092-F19EDDB8-BE99-4661-BFCC-FD3F0CD075D3 Q36652599-D42D23C3-68DA-40B8-A6C4-89FA7234A552 Q36702987-EAA0B4F1-C24D-4FE6-ACD2-35B5CE60136A Q36802630-93673D7C-D559-4889-9222-F1D5FAA7EC6B Q37052790-441EEF5A-4CB0-4144-A368-B5B2E5935C0D Q37290599-BF4BCAEF-BC24-403E-8E69-9AEE3637B794 Q37353434-9261123A-55CC-4CD6-8D08-AF59AA309D19 Q37428670-84849A97-4791-4465-85D3-DDF24DEA92B2 Q37485056-472B0772-8A2A-419B-A300-549ACB9DD83C Q37707806-3BD98574-D10D-40E1-81A8-5BBA1A1814FF Q37879203-3C1EFF50-B937-4590-BA56-66B2482F6CF8 Q38027179-73A2802F-644C-4118-A7F2-C69EFCDAA86A Q38303998-C6779046-1D46-4E7D-AF45-D93D4A1398F9 Q39413284-40F0195C-08D8-4757-9620-73B8731AC327 Q41984797-B0719519-27A6-4512-9E39-95DD3BDC848F Q42723597-79EB13D5-F4EC-4408-95A4-AB1B2B9ED9BD Q45580143-BF11C912-FC3C-4CDD-9329-5F6B9C728A94 Q47334799-BB1139BF-76B1-4BEA-8B73-545834B56478 Q48015887-48CCE6E7-4653-43AC-8CDF-29DD10278C8F Q48016667-80D8DEA1-7116-4A39-8044-5FD1E2032BDE Q51660440-A558B55B-C990-4927-B205-978233C5FBEC Q56403247-2E9DFB7B-1DC2-49DE-953B-7916EFFAEB1A

P2860

Randomized trial of 3-dose regimens of tafenoquine (WR238605) versus low-dose primaquine for preventing Plasmodium vivax malaria relapse.

http://www.wikidata.org/entity/Q41913336

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

2004年论文

@zh

2004年论文

@zh-cn

name

Randomized trial of 3-dose reg ...... smodium vivax malaria relapse.

@en

type

label

Randomized trial of 3-dose reg ...... smodium vivax malaria relapse.

@en

prefLabel

Randomized trial of 3-dose reg ...... smodium vivax malaria relapse.

@en

P1433

Q41913336-983B1806-7764-4EF2-AF5F-D26C37097C6A

P1476

Q41913336-B45B7CE9-C422-4B2F-B4C1-E98258B8F563

P2093

Q41913336-2E850D93-3327-4451-8805-3F8CF2A77195

Q41913336-8EBF8314-5D33-42FD-BC9F-3B54B9701085

Q41913336-97500BB5-1D0E-45E5-A3BA-6BAD7EBD2B22

Q41913336-A566BABD-B435-4C44-A12E-FDEF6884679F

Q41913336-DA560DE4-0126-469E-B907-2D506729501B

Q41913336-EE97F929-AB75-4C50-8FDF-802E1F367958

P2860

Q41913336-521CD992-E37D-46F0-8F3B-4060B4F0F568

Q41913336-6E92F68B-5905-44BE-8A20-DD1134017172

Q41913336-8B8EEF7D-D916-46EC-BD17-30875192DA5E

Q41913336-9583121E-4A65-4EB3-8F1F-B62F17BFF193

Q41913336-9B528DE4-987E-4F0C-9C47-256612ACB0DA

Q41913336-AF76E3B4-9B40-4B3B-A751-A38EC53711AB

Q41913336-B51E9B3F-4B15-475B-8C6F-F5F26782A8FA

Q41913336-DBB430A2-57D2-40A7-9540-18BEC38EF7B8

Q41913336-F64AF9C3-9D28-4759-ABB3-AF4679C7E6CF

Q41913336-FE9F0197-A38F-428D-B54B-F2E59C39D7A3

P304

Q41913336-F8958672-C1A4-4F8E-8994-E897B63C7A49

P31

Q41913336-D03B8CE3-9FE4-4110-AB60-199BF786CECD

P356

Q41913336-279E0C59-1B77-415A-B0A8-3C9288DAC8BA

P407

Q41913336-3CC4B533-AE4C-423C-AFA0-3F0A4F30ACB5

P433

Q41913336-FA59C205-29CD-4430-9C5E-C0B7BF6F7835

P478

Q41913336-35062886-A218-4E44-BA7B-D8617698C621

P50

Q41913336-06A50DC3-6BF4-4E32-B7CE-530706327F26

Q41913336-07176CFF-6B0A-432D-AC5C-EE379A49B782

Q41913336-590D6E10-F032-4A23-81C1-AD1126D39FD5

Q41913336-936DC1C9-18A6-45D3-BB21-F511BE3DFB49

P577

Q41913336-0EE04E8D-600C-460F-849B-F64348DE99C0

P5875

Q41913336-8F8F1F6C-16A7-4680-ADA3-B10E25864379

P698

Q41913336-26200BBD-C87A-438E-8E0F-0346532BC58E

P921

Q41913336-59DE344F-3E47-4F5A-BFA9-456EAA37D1E4

Q41913336-9F700B7C-FC24-49EC-A808-B123C7458ABF

Q41913336-C767536A-1FA5-40B2-BDBD-76090BED37E6

P356

P1433

Clinical Infectious Diseases

P1476

Randomized trial of 3-dose reg ...... smodium vivax malaria relapse.

@en

P2093

D Gray Heppner

http://www.w3.org/2001/XMLSchema#string

Douglas B Tang

http://www.w3.org/2001/XMLSchema#string

Douglas S Walsh

http://www.w3.org/2001/XMLSchema#string

Duangsuda Siriyanonda

http://www.w3.org/2001/XMLSchema#string

Udomsak Silachamroon

http://www.w3.org/2001/XMLSchema#string

Weerapong Phumratanaprapin

http://www.w3.org/2001/XMLSchema#string

P2860

A new primaquine analogue, tafenoquine (WR 238605), for prophylaxis against Plasmodium falciparum malaria

Vivax malaria resistant to treatment and prophylaxis with chloroquine.

High dose of primaquine in primaquine resistant vivax malaria.

Primaquine-tolerant vivax malaria in Thailand.

Randomized dose-ranging study of the safety and efficacy of WR 238605 (Tafenoquine) in the prevention of relapse of Plasmodium vivax malaria in Thailand.

The efficacy of WR238605 against the blood stages of a chloroquine resistant strain of Plasmodium vivax.

A randomized, double-blind, placebo-controlled, dose-ranging trial of tafenoquine for weekly prophylaxis against Plasmodium falciparum.

Comparison of tafenoquine (WR238605) and primaquine in the post-exposure (terminal) prophylaxis of vivax malaria in Australian Defence Force personnel.

Blood schizontocidal activity of WR 238605 (Tafenoquine) against Plasmodium cynomolgi and Plasmodium fragile infections in rhesus monkeys.

Measurement of tafenoquine (WR 238605) in human plasma and venous and capillary blood by high-pressure liquid chromatography.

P304

1095-1103

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1086/424508

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

39

http://www.w3.org/2001/XMLSchema#string

P50

Sornchai Looareesuwan

Srivicha Krudsood

Thomas G Brewer

Polrat Wilairatana

P577

2004-09-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8229598

http://www.w3.org/2001/XMLSchema#string

P698

15486831

http://www.w3.org/2001/XMLSchema#string

P921

Plasmodium vivax

malaria prevention